Vigil Neuro
Abbie Renoux is a Principal Scientist at Vigil Neuroscience, with previous experience as a Senior Scientist at Triplet Therapeutics. Abbie's expertise lies in cell biology assay development for trinucleotide repeat disorders. Prior to their current roles, Abbie held positions at Proclara Biosciences, Tufts University, and the University of Michigan, where they conducted research in neuroscience and molecular and integrative physiology. Abbie holds a PhD in Molecular and Integrative Physiology from the University of Michigan and a Bachelor of Science in MCDB and Biochemistry from the University of Colorado Boulder.
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.